Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Nasopharyngeal Carcinoma 39Carcinoma, Non-Small-Cell Lung 30Esophageal Squamous Cell Carcinoma 23Carcinoma, Hepatocellular 21Triple Negative Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Breast Neoplasms 17Advanced Solid Tumor 17Stomach Neoplasms 14Melanoma 14Small Cell Lung Carcinoma 13Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 10Carcinoma, Transitional Cell 10Carcinoma, Renal Cell 10Recurrence 9Head and Neck Neoplasms 8Solid Tumor 7Sarcoma 7Neoplasm Metastasis 7Liver Neoplasms 7Urinary Bladder Neoplasms 5Rectal Neoplasms 5Esophageal Neoplasms 5Advanced Solid Tumors 5Pancreatic Neoplasms 4Nasopharyngeal Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4

Interventions

Gemcitabine 92Cisplatin 70Oxaliplatin 37Capecitabine 37durvalumab 29Fluorouracil 26pembrolizumab 24Leucovorin 22S 1 (combination) 18Nivolumab 13Irinotecan 13Bevacizumab 13lenvatinib 12tremelimumab 10apatinib 8Trastuzumab 7Injections 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7Paclitaxel 6Immune Checkpoint Inhibitors 6Docetaxel 6titanium silicide 5surufatinib 5envafolimab 5camrelizumab 5atezolizumab 5Folfox protocol 5Drug Therapy 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Biliary Tract Neoplasms × toripalimab × Clear all
NCT07619235 2026-06-01

A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

Huazhong University of Science and Technology

Phase 4 Not yet recruiting
32 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
65 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT04010071 2023-03-29

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Peking Union Medical College Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡